Secondary acute lymphoblastic leukemia (sALL) following acute myeloid leukemia (AML) is a rare event; only eight cases have been reported. We report a patient with acute promyelocytic leukemia (APL), in hematological and molecular remission who developed T-ALL three years after the diagnosis of APL. The morphological, cytochemical, phenotypical and molecular features of this T-ALL were differen...

Recent reviews on acute promyelocytic leukemia (APL) treatment have focused on comparing therapeutic approaches, including all-trans retinoic acid (ATRA) and chemotherapy, and do not address several other aspects of APL management that are relevant to the outcome in individual patients. These aspects include appropriate diagnostic tools and strategies, supportive care, recognition and treatment...

Acute promyelocytic leukemia (APL) is an acute myeloid leukemia characterized by leukemic cells blocked at the promyelocytic stage of granulocytic differentiation. According to the FrenchAmerican-British (FAB) classification, two main cytological subtypes are recognized: (i) classical hypergranular promyelocytic leukemia (M3) and (ii) the microgranular promyelocytic leukemia variant (M3v). Rece...

Antiphospholipid antibodies (aPL) have been found in the blood of patients with systemic and neurological disease. The rare reports of aPL in cerebral spinal fluid (CSF) have been limited mostly to IgG and IgM anticardiolipin (aCL). Our published finding of IgA aPE in the CSF of a young stroke victim prompted us to establish "normal" CSF aPL values for a panel of aPL, which included aCL, antiph...

OBJECTIVES Antiphospholipid antibodies (aPL) have been associated with syndromes involving thrombosis, fetal loss and thrombocytopenia. Genetic and environmental conditions are among the factors attributed to the cause of autoimmune diseases such as the antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The aim of this study was to determine whether these factors determine ...

in the French–American and British (FAB) classification and represents approximately 5—10% of all leukemia in adults. In about 95—98% of the cases, APL is associated with the reciprocal translocation, t(15; 17)(q22; q21) and the reciprocal fusion of the retinoic acid receptor (RAR)a gene on chromosome 17 with the promyelocytic leukemia (PML) gene on chromosome 15. The resulting PML-RARa fusion ...

Background: Acute myeloblastic leukemia (AML) is a clonal disorder due to bone marrow failure and uncontrolled proliferation of myeloid lineage. Acute promyelocytic leukemia (APL) is a subtype of AML. Heterocyclic compounds, such as indole, are considered as attractive candidates for cancer therapy, due to their abundance in nature and known biological activity. Sal-like protein (SALL4) is a zi...

The PML-RAR alpha fusion protein is central to the pathogenesis of acute promyelocytic leukemia (APL). Expression of this protein in transgenic mice initiates myeloid leukemias with features of human APL, but only after a long latency (8.5 months in MRP8 PML-RARA mice). Thus, additional changes contribute to leukemic transformation. Activating mutations of the FLT3 receptor tyrosine kinase are ...

The persistent presence in plasma of medium to high levels of IgG and/or IgM class anticardiolipin antibodies (aCL) and/or the lupus anticoagulant (LAC) is associated with both “recurrent pregnancy loss” and venous and arterial thrombosis. This clinicoserological entity, first described in the early eighties in patients with systemic lupus erythematosus was termed the antiphospholipid syndrome ...